BRAF and neoplasm: The phase 1b PNOC014 (NCT03429803) clinical trial evaluated the safety and tolerability of tovorafenib monotherapy across a dose range up to 530 mg m−2 per week, providing early evidence of anti-tumor activity in patients with BRAF-altered relapsed/refractory pLGG, and supported the selected phase 2 dose of 420 mg m−2 (maximum dose 600 mg) administered orally once per week29.